Adjuvant Dexmedetomidine and Tramadol in Subcostal Transversus Abdominis Plan Block

• Status: Completed
• Trial end date: 2023-04-03
• Target enrollment: 0
• Participant gender: All

Summary

In this study, dexmedetomidine and tramadol were added as adjuvant to bupivacaine in transversus abdominis plane block (TAP), intraoperative hemodynamics, opioid consumption, muscle relaxant use, postoperative analgesic effects and side effects (such as nausea-vomiting) were evaluated.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Yuzuncu Yıl University
• Treatments: Bupivacaine; Dexmedetomidine; Tramadol

Criteria

Inclusion Criteria:

• 20-60 years old

• Those who will undergo elective laparoscopic cholecystectomy surgery

• Those in ASA I-II physical status

• Those who gave consent to participate in the study

Exclusion Criteria:

• Those outside the age range of 20-60

• Those outside of ASA I-II physical status

• Serious heart, lung, liver disease

• Kidney failure

• Bleeding diathesis

• Those who develop complications during the procedure

• Those with fever, active infection

• Those who are allergic to the drugs to be used

• Those who refused to participate in the study

• Those with hypothermic and acid-base disorders

• Electrolyte disturbances such as hypokalemia, hypocalcemia

• Those taking antibiotics, anticonvulsants, antiarrhythmics, cholinesterase inhibitors

• Pregnant

• Those with bleeding

• BMI 30 and above